SGLT2 Inhibitors Linked to Lower Epilepsy Risk - Summary - MDSpire
From the Journals

SGLT2 Inhibitors Linked to Lower Epilepsy Risk

Real-world cohort data show lower epilepsy risk vs DPP-4 inhibitors in older patients with type 2 diabetes

Share

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are linked to significantly reduced risks of late-onset epilepsy, status epilepticus, and the need for antiseizure medications in patients over 60 with type 2 diabetes, as revealed by a study involving over 1.4 million patients. The observational study found that SGLT2 inhibitors were associated with a 45% lower incidence of late-onset epilepsy compared to dipeptidyl peptidase-4 (DPP-4) inhibitors, along with substantial reductions in status epilepticus and antiseizure medication initiation. However, limitations include reliance on coded diagnoses and missing neuroimaging data.

Original Source(s)

SGLT2 Inhibitors Linked to Lower Epilepsy Risk

  • by Kathryn Wighton

  • April 7, 2026

Related Content

Hospital-Treated Infections Linked to Dementia Risk

Investigators identify 29 conditions associated with dementia risk in nationwide registry analysis.

Alzheimer’s Drug Lecanemab Works by “Switching On” the Brain’s Cleanup Cells

Study reveals Fc fragment of antibody is essential for activating microglia to clear amyloid plaques

  • April 7, 2026

  • 3 min
The Hidden Diversity of Amyloid Plaques

A multimodal MSI approach reveals how plaque-associated lipid signatures differ across brain regions in Alzheimer’s disease